Ovarian cancer

By G. Jayson, E. Kohn, H. Kitchener, Jonathan A. Ledermann. The Lancet, 2014

667 citations recorded by the source corpus.

Subfields: Genetics, Oncology, Reproductive Medicine

View Paper: https://www.semanticscholar.org/paper/bddccb328536ca6fa4c42f603b6801d136498f33

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. N. Colombo
2. U. Matulonis
3. A. Oaknin
4. R. Shapira-Frommer
5. A. Lisyanskaya
6. A. Santin
7. J. Ledermann
8. S. Pignata

Citations in the corpus

• Antitumor Activity and Safety of Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer: Results from the Phase 2 KEYNOTE-100 Study. (2019, background): “Most women are diagnosed at a later stage and, despite response to initial platinum-based chemotherapy, the majority will develop recurrent cancer and die of their cancer [2, 3].”